MER3101 MAS-1 Adjuvanted Antigen-specific Immunotherapeutic
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MER3101 MAS-1 Adjuvanted Antigen-specific Immunotherapeutic, covering 2026-02-13 to 2026-02-13. Get the full timeline:
Most recent: Clinical Trial Update: MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes [Phase 1]